Marketed as Mounjaro for the treatment of type 2 diabetes, the drug was subsequently approved as Zepbound for obesity by the FDA in November 2023
No funding was received for this study or to assist with the preparation of this manuscript
If you are not a good candidate for GLP-1 agonists, our providers will offer different modalities of weight loss for you, including alternative medications, lifestyle modification, continuous glucose monitoring, and other tools
Our surgery and imaging services will stay at their current locations and our team members remain committed to providing world-class patient care and services to our community
Obesity is a major risk factor for cardiovascular disease, the leading cause of death in people with common arthritides such as osteoarthritis (OA), gout, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
Will insurance still pay for GLP-1s even after people lose weight